| Identification | Back Directory | [Name]
4,10-DIOXATRICYCLO[5.2.1.0(2,6)]DEC-8-ENE-3,5-DIONE | [CAS]
5426-09-5 | [Synonyms]
AKOS 92618
TIMTEC-BB SBB007745
7-Oxanorborna-2-ene-5,6-dicarboxylic anhydride
3,6-EPOXY-1,2,3,6-TETRAHYDROPHTHALIC ANHYDRIDE
3,6-ENDOXO-1,2,3,6-TETRAHYDROPHTHALIC ANHYDRIDE
3-dione,3a,4,7,7a-tetrahydro-7-epoxyisobenzofuran-1
4,10-DIOXATRICYCLO[5.2.1.0(2,6)]DEC-8-ENE-3,5-DIONE
4,10-Dioxatricyclo[5.2.1.02,6]decane-8-ene-3,5-dione
3a,4,7,7a-Tetrahydro-4,7-epoxy-1,3-isobenzofurandione
4,7-Epoxyisobenzofuran-1,3-dione, 3a,4,7,7a-tetrahydro-
7-OXABICYCLO[2.2.1]-5-HEPTENE-2,3-DICARBOXYLIC ANHYDRIDE
7-Oxabicyclo[2.2.1]heptane-5-ene-2,3-dicarboxylic anhydride | [Molecular Formula]
C8H6O4 | [MDL Number]
MFCD00077442 | [MOL File]
5426-09-5.mol | [Molecular Weight]
166.13 |
| Hazard Information | Back Directory | [Uses]
4,10-Dioxatri cyclo[5.2. 1.02.6]dec-8-ene-3,5-dione is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | [References]
[1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
| Spectrum Detail | Back Directory | [Spectrum Detail]
4,10-DIOXATRICYCLO[5.2.1.0(2,6)]DEC-8-ENE-3,5-DIONE(5426-09-5)MS
4,10-DIOXATRICYCLO[5.2.1.0(2,6)]DEC-8-ENE-3,5-DIONE(5426-09-5)1HNMR
4,10-DIOXATRICYCLO[5.2.1.0(2,6)]DEC-8-ENE-3,5-DIONE(5426-09-5)13CNMR
4,10-DIOXATRICYCLO[5.2.1.0(2,6)]DEC-8-ENE-3,5-DIONE(5426-09-5)IR1
4,10-DIOXATRICYCLO[5.2.1.0(2,6)]DEC-8-ENE-3,5-DIONE(5426-09-5)IR2
|
|
|